Stocks to Buy on Do...
Health Care: Drugs
Shire PLC (SHPGY: NASDAQ)
$103.43 -0.46 | -0.44%
02/08/12 - 04:00 PM ET
358.11K / 429.70K
Vol / Avg. Vol:103.99 / 103.89
Open / Prev. Close:102.68 - 104.22
Today's Range:79.02 - 105.53
52 Wk Range:-0.45%
Performance YTD:TheStreet Rating:
Portfolios with SHPGY
- Portfolio NameUser Type
- ContributorRocket Stocks for the Week ...
- Contributor10 Pharmaceutical Stocks Wi...
- ProFidelity Select Pharmaceuti...
- Contributor10 Biotech Stocks Facing FD...
- UserPART 4 JPMorgan 28th Annual...
- UserDartrx Portfolio 1
- ContributorBarron's 2009 Roundtable Pi...
- UserPART 4 JPMorgan 27th Annual...
- UserBarron's Summary 6-14-2008
- UserBarron's Research Reports 5...
Latest SHPGY Headlines from TheStreet
- SHPGY: Trading Along the Flatline 11.28.11 | 11:11 am
- Shire Plc's CEO Discusses Q3 2011 Results - Earnings Call Transcript 10.28.11 | 04:10 pm
- Shire Stock To Go Ex-dividend Tomorrow (SHPGY) 09.06.11 | 09:09 am
- Shire Plc's CEO Discusses Q2 2011 Results - Earnings Call Transcript 07.28.11 | 07:07 pm
- Shire Reaches New 52-Week High (SHPGY) 07.21.11 | 11:07 am
- Shire Stock Hits New 52-Week High (SHPGY) 07.13.11 | 10:07 am
- Shire Reaches New 52-Week High (SHPGY) 05.11.11 | 11:05 am
- Shire Stock Hits New 52-Week High (SHPGY) 04.27.11 | 10:04 am
- Shire Stock Hits New 52-Week High (SHPGY) 04.08.11 | 09:04 am
- Shire Stock Hits New 52-Week High (SHPGY) 03.18.11 | 10:03 am
Press Releases for SHPGY
- Vyvanse(R) (lisdexamfetamine Dimesylate) Capsules, (CII) Now Approved In The US For Maintenance Treatment In Adults With ADHD - PR Newswire 02.07.12 | 12:02 pm
- Shire And Sangamo Collaborate To Develop Therapeutics For The Treatment Of Hemophilia And Other Monogenic Diseases - PR Newswire 02.01.12 | 07:02 am
- Shire And Sangamo Collaborate To Develop Therapeutics For The Treatment Of Hemophilia And Other Monogenic Diseases - PR Newswire 02.01.12 | 07:02 am
- Prasco® Launches Authorized Generic Of Shire's Carbatrol® - PR Newswire 01.12.12 | 09:01 am
- Shire Acquires US Rights To Resolor(R) (prucalopride) - PR Newswire 01.10.12 | 10:01 am
- Shire Acquires US Rights To Resolor® (prucalopride) - PR Newswire 01.10.12 | 07:01 am
- Shire's Venvanse® (Lisdexamfetamine Dimesylate) Marketing Application Accepted For Review In Europe - PR Newswire 01.05.12 | 08:01 am
- Shire Reports Positive Phase II Results For Investigative Use Of Vyvanse® (lisdexamfetamine Dimesylate) Capsules, (CII) - PR Newswire 12.08.11 | 07:12 am
- BetterInvesting Magazine Releases February Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use - PR Newswire 12.05.11 | 05:12 pm
- Shire Announces Regulatory Filings In US And EU For New Manufacturing Facility - PR Newswire 11.22.11 | 02:11 pm
Partner Headlines for SHPGY
- Sanofi Gets Nod for Framingham Unit - Analyst Blog - Zacks 01.20.12 | 04:01 pm
- End-of-Day Market Summary for December 2, 2011 - Benzinga 12.02.11 | 04:12 pm
- Shire and FDA Agree on Study Proposal to Confirm Midrodrine Benefit - Benzinga 12.02.11 | 04:12 pm
- Top 5 Nasdaq 100 Stocks To Consider Now - Seeking Alpha 11.21.11 | 08:11 am
- 38 Dividend Increases Expected In The Next 10 Weeks - Seeking Alpha 08.26.11 | 09:08 am
- Watson Entangled in Legal Dispute - Analyst Blog - Zacks 07.08.11 | 10:07 am
- Shire Entangled in Legal Dispute - Analyst Blog - Zacks 07.06.11 | 06:07 pm
- Safeguard Scientifics Realizes $145.4 Million in Aggregate Cash Proceeds from Shires Acquisition of Advanced BioHealing - Benzinga 06.28.11 | 09:06 am
- Shire to Produce More Replagal - Analyst Blog - Zacks 06.27.11 | 07:06 pm
- European Authorities Approve New Manufacturing Facility for Shire's REPLAGAL - Benzinga 06.24.11 | 09:06 am
